Data / New clinical trials / Ovarian Neoplasms

Ovarian Neoplasms trials: 387 new since Nov 2024

Name: New Ovarian Neoplasms clinical trials
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

The full list. New Ovarian Neoplasms clinical trials: 387 rows for $19.35, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 17 rows a month. The new rows come each week by email, $19 a month.

Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery. The rows on this page are a sample.

For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/condition/ovarian-neoplasms, and every list with its row count and price is at https://specstream.ai/data/lists.json.

Updated November 9, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).

387 clinical studies in Ovarian Neoplasms were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 149 have an industry sponsor and 327 are recruiting or about to. The newest, NCT07926048, was posted on November 9, 2026: A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Qilu Pharmaceutical Co., Ltd.).

The request: Every new Ovarian Neoplasms clinical trial on ClinicalTrials.gov, with the sponsor, phase, sites and the listed contact. $10 of credit on sign-up, no card.

Get new trials like these Watch a sponsor

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

387New trials
149Industry sponsored
327Recruiting or not yet
November 9, 2026Latest posted

Newest trials

The newest 100 of 387, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

First posted	NCT ID	Title	Sponsor	Phase	Status	Conditions	Enrollment	Countries	Source
November 9, 2026	NCT07926048	A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Qilu Pharmaceutical Co., Ltd.	Phase 3	Not yet recruiting	Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	420		clinicaltrials.gov
November 6, 2026	NCT07923214	A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors	Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.	Phase 1	Recruiting	Advanced Solid Tumors, Breast Cancer, Ovarian Cancer, Gastric Cancer, Other Solid Tumors	30	China	clinicaltrials.gov
November 4, 2026	NCT07915336	Peer Ambassador in Gyn Onc Trials	Abramson Cancer Center at Penn Medicine	Not applicable	Enrolling by invitation	Ovarian Cancer	125	United States	clinicaltrials.gov
November 2, 2026	NCT07909031	CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors	Crescent Biopharma, Inc.	Phase 1/2	Recruiting	Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)...	219	United States	clinicaltrials.gov
October 29, 2026	NCT07905677	Phase 1 Study of VT-101 in Advanced Ovarian Cancer	Michael J. Goodheart	Phase 1	Recruiting	Epithelial Ovarian Cancer, Ovarian Cancer	22	United States	clinicaltrials.gov
October 28, 2026	NCT07902375	Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers	Universiteit Antwerpen	Not applicable	Recruiting	Gynaecological Cancers, Ovarian Cancer, Endometrial Cancer, Vulvar Cancer, Vaginal Cancer, Postmenopausal Bleeding...	730	Belgium	clinicaltrials.gov
October 27, 2026	NCT07896421	Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and...	AbbVie	Observational	Recruiting	Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer...	500	Austria	clinicaltrials.gov
October 26, 2026	NCT07895212	Feasibility of the "One-Finger Technique" for Identifying the Upper Left Ureter During Para-Aortic Lymphadenectomy	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Not applicable	Recruiting	Ovary Cancer, Cervical Cancer, Endometrial Cancer	40	China	clinicaltrials.gov
October 26, 2026	NCT07894874	A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors.	InventisBio Yiqi Beijing Limited	Phase 1	Not yet recruiting	Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer	204		clinicaltrials.gov
October 22, 2026	NCT07889843	Folate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian Cancer	Hellenic Cooperative Oncology Group	Observational	Recruiting	High Grade Serous Ovarian Cancer, Folate Receptor Alpha Positive	200	Greece	clinicaltrials.gov
October 20, 2026	NCT07883798	Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions	Affidea Nu-med Center of Oncological DIagnostics and Therapy	Observational	Recruiting	Cervical Cancer, Gynecologic Cancer, Endometrial Cancer, Uterine Cancer, Uterine Sarcoma, Ovarian Cancer, Fallopian...	500	Poland	clinicaltrials.gov
October 20, 2026	NCT07883551	AI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant Before Surgery	Catharina Ziekenhuis Eindhoven	Observational	Not yet recruiting	Ovarian Cancer, Ovarian Tumor, Borderline Ovarian Tumor	1,300	Belgium, Netherlands	clinicaltrials.gov
October 20, 2026	NCT07882485	Effects of Web-Based Ovarian Cancer Awareness Education on Women's Health Beliefs and Risk-Reducing Behaviors	Ege University	Not applicable	Not yet recruiting	Ovarian Cancer	82		clinicaltrials.gov
October 15, 2026	NCT07876349	EHR Intervention to Increase HBOC Genetic Testing	Columbia University	Not applicable	Recruiting	Breast Cancer, Ovarian Cancer, Hereditary Cancer Syndrome	55	United States	clinicaltrials.gov
October 13, 2026	NCT07872644	Safety in Ovarian Cancer for Average-Risk Women - Analysis	Mercy BioAnalytics, Inc.	Not applicable	Not yet recruiting	Ovarian Cancer	1,750	United States	clinicaltrials.gov
October 13, 2026	NCT07870278	A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)	Merck Sharp & Dohme LLC	Phase 1	Not yet recruiting	Ovarian Neoplasms, Endometrial Neoplasms	80		clinicaltrials.gov
October 9, 2026	NCT07869186	Dermatological Effects and Quality of Life in Oncology Patients	European Institute of Oncology	Not applicable	Not yet recruiting	Breast Cancer, Ovarian Cancer, NSCLC (Non-small Cell Lung Cancer), Melanoma (Skin Cancer), Gynecological Cancer	300	Italy	clinicaltrials.gov
October 6, 2026	NCT07860203	Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery	Catherin Zhang	Not applicable	Recruiting	Uterine Fibroids (Leiomyoma), Adenomyosis of Uterus, Endometriosis, Endometrial Cancer, Cervical Cancer, Ovarian Cancer	100	China	clinicaltrials.gov
October 5, 2026	NCT07859215	Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line...	Genmab	Phase 3	Not yet recruiting	Ovarian Cancer	602		clinicaltrials.gov
September 30, 2026	NCT07849543	Contrast-enhanced Ultrasound Evaluation of Indeterminate Ovarian Lesions: Prospective Multicenter Study	Thomas Jefferson University	Not applicable	Not yet recruiting	Ovarian Cancer, Adnexal Lesion	190		clinicaltrials.gov
September 28, 2026	NCT07843303	Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer	Peking University Cancer Hospital & Institute	Phase 2	Not yet recruiting	Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer	53	China	clinicaltrials.gov
September 21, 2026	NCT07832227	Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial	Dana-Farber Cancer Institute	Phase 2	Not yet recruiting	Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer	60		clinicaltrials.gov
September 16, 2026	NCT07822646	A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer	Chinese PLA General Hospital	Phase 3	Recruiting	Ovarian Cancer	120	China	clinicaltrials.gov
September 14, 2026	NCT07816666	Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer	AstraZeneca	Phase 3	Recruiting	Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer...	600	Australia, Brazil, Canada, China, Germany, India, Italy, Japan, South Korea...	clinicaltrials.gov
September 11, 2026	NCT07815951	Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors	Yong He	Phase 1	Not yet recruiting	Solid Tumors, Carcinoma, Ovarian Neoplasms, Endometrial Neoplasms Malignant, Testicular Neoplasms, Lung Neoplasms...	8	China	clinicaltrials.gov
September 11, 2026	NCT07815704	Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin	University of Colorado, Denver	Phase 2	Not yet recruiting	Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer, High Grade Serous Adenocarcinoma of Ovary	40	United States	clinicaltrials.gov
September 11, 2026	NCT07814872	A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment	Harvard Medical School (HMS and HSDM)	Observational	Not yet recruiting	Neoplasms (Cancer / Tumors), Colorectal Neoplasms, Lung Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Pancreatic...	30,000	United States	clinicaltrials.gov
September 10, 2026	NCT07814248	A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a...	TwoStep Therapeutics, Inc.	Phase 1	Recruiting	NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric...	74	United States	clinicaltrials.gov
September 10, 2026	NCT07811297	A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers	Advenchen Pharmaceuticals, LLC.	Phase 1/2	Not yet recruiting	Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma	138	United States	clinicaltrials.gov
September 9, 2026	NCT07809659	CanRisk-Based Ovarian Cancer Risk Assessment Versus Standard Practice (DISARM CSA)	Instituto Portugues Oncologia de Lisboa Francisco Gentil	Not applicable	Recruiting	Ovarian Cancer	2,130	Czechia, Greece, Lithuania, Portugal	clinicaltrials.gov
September 8, 2026	NCT07808320	HERCULES: Ultrasound-Based Liver Involvement Classification in Ovarian Cancer	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Observational	Not yet recruiting	Ovarian Cancer, Recurrent Ovarian Cancer	20	Italy	clinicaltrials.gov
September 8, 2026	NCT07807956	A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With...	AbbVie	Phase 1	Recruiting	Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer...	130	United States	clinicaltrials.gov
September 8, 2026	NCT07807683	Circulating Endothelial Cells (CECs) as Potential Predictive/Prognostic Biomarkers in Ovarian Cancer	Centro di Riferimento Oncologico - Aviano	Observational	Completed	Ovarian Cancer	148		clinicaltrials.gov
September 1, 2026	NCT07797283	Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing...	Incyte Corporation	Phase 3	Not yet recruiting	Ovarian Cancer	590		clinicaltrials.gov
August 28, 2026	NCT07793201	Machine Learning Algorithms Incorporating Radiomic Ultrasound Features	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Observational	Not yet recruiting	Adnexal Masses	12,000	Italy	clinicaltrials.gov
August 28, 2026	NCT07791732	A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent...	Daiichi Sankyo	Phase 3	Not yet recruiting	Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian	600		clinicaltrials.gov
August 27, 2026	NCT07790939	89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer	Peking University Cancer Hospital & Institute	Early phase 1	Not yet recruiting	Epithelial Ovarian Cancer, Ovarian Cancer	20		clinicaltrials.gov
August 24, 2026	NCT07783022	Real-World Study of Niraparib in First-Line Maintenance Therapy for Advanced Epithelial Ovarian Cancer	Fudan University	Observational	Recruiting	Ovarian Cancer	1,920	China	clinicaltrials.gov
August 24, 2026	NCT07782164	Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)	Amsterdam UMC, location VUmc	Observational	Recruiting	Colorectal Carcinoma, Renal Cancer, Bladder Cancer, Cervical Cancer, Prostate Cancer, Ovarian Cancer, Lung Cancer...	27	Netherlands	clinicaltrials.gov
August 24, 2026	NCT07781852	Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer	Lumina Pharmaceuticals Inc	Early phase 1	Not yet recruiting	Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC)...	40	United States	clinicaltrials.gov
August 21, 2026	NCT07779538	Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Phase 3	Recruiting	Ovarian Cancer	420	China	clinicaltrials.gov
August 21, 2026	NCT07778498	A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.	Phrontline Biopharma	Phase 1/2	Recruiting	Ovarian Cancer	150	China, United States	clinicaltrials.gov
August 20, 2026	NCT07776691	A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian...	Merck Sharp & Dohme LLC	Phase 3	Recruiting	Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer	802	Israel, South Korea, Taiwan, United Kingdom, United States	clinicaltrials.gov
August 20, 2026	NCT07776171	Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent...	Sun Yat-sen University	Phase 2	Not yet recruiting	Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)	176	China	clinicaltrials.gov
August 18, 2026	NCT07771400	Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients	Latin American Cooperative Oncology Group	Observational	Not yet recruiting	Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Fallopian Tube Cancer Stage III...	320	Argentina, Brazil, Colombia, Mexico	clinicaltrials.gov
August 14, 2026	NCT07764744	Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants	Weill Medical College of Cornell University	Not applicable	Not yet recruiting	Ovarian Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Serous Tubal Intraepithelial Carcinoma, Early Detection...	70	United States	clinicaltrials.gov
August 12, 2026	NCT07761416	Opportunistic Salpingectomy During Bariatric Surgery for Ovarian Cancer Prevention	St. Joseph's Healthcare Hamilton	Early phase 1	Not yet recruiting	Ovarian Cancer, Bariatric Surgery, Opportunistic Salpingectomy	66		clinicaltrials.gov
August 12, 2026	NCT07760012	68Ga-SorB PET/CT Imaging in Patients With Solid Tumors	Peking University Third Hospital	Not applicable	Recruiting	Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer, Pancreatic Cancer, Ovarian Cancer...	50	China	clinicaltrials.gov
August 11, 2026	NCT07757711	Implementation of New Models of Ovarian Carcinoma Resistant to Therapy	Mario Negri Institute for Pharmacological Research	Observational	Not yet recruiting	Ovarian Cancer	50		clinicaltrials.gov
August 10, 2026	NCT07755436	Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic...	ArriVent BioPharma, Inc.	Phase 1	Recruiting	Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer, Metastatic...	180	United States	clinicaltrials.gov
August 7, 2026	NCT07752875	A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation	LG Chem	Phase 1/2	Not yet recruiting	Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast...	250		clinicaltrials.gov
August 6, 2026	NCT07749586	A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors	Arvinas Inc.	Phase 1/2	Recruiting	Advanced Solid Tumor	499	United States	clinicaltrials.gov
August 5, 2026	NCT07747506	Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)	Verastem, Inc.	Phase 2	Not yet recruiting	Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer	2	France	clinicaltrials.gov
August 3, 2026	NCT07743164	A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed...	Merck Sharp & Dohme LLC	Phase 3	Recruiting	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	646	Israel, Taiwan, United States	clinicaltrials.gov
August 3, 2026	NCT07741968	A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer	City of Hope Medical Center	Not applicable	Recruiting	Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC...	126	United States	clinicaltrials.gov
July 30, 2026	NCT07736937	Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer	Gilead Sciences	Phase 1/2	Recruiting	Ovarian Cancer	72	Belgium, Ukraine, United States	clinicaltrials.gov
July 29, 2026	NCT07733505	Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian...	Odense University Hospital	Phase 1	Recruiting	Ovarian Cancer	10	Denmark	clinicaltrials.gov
July 29, 2026	NCT07732686	Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry	University of Oklahoma	Observational	Not yet recruiting	Pancreas Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Cancer, Colon...	2,000	United States	clinicaltrials.gov
July 23, 2026	NCT07724106	A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With...	West China Hospital	Phase 1	Recruiting	Ovarian Cancer, mRNA Vaccine	9	China	clinicaltrials.gov
July 22, 2026	NCT07720180	Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide...	Medical University of South Carolina	Phase 2	Not yet recruiting	Ovarian Cancer	20	United States	clinicaltrials.gov
July 22, 2026	NCT07718854	Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer	Tufts Medical Center	Phase 2	Recruiting	Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer, Recurrent Ovarian Clear Cell Adenocarcinoma	50	United States	clinicaltrials.gov
July 21, 2026	NCT07716800	Predictors of Cognitive Decline and Delirium in Older Women With Ovarian Cancer	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Observational	Not yet recruiting	Ovarian Cancer, Cognitive Decline, Delirium	205		clinicaltrials.gov
July 20, 2026	NCT07715747	A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors	TJ Biopharma Co., Ltd.	Phase 1	Recruiting	Solid Tumor, Metastatic Ovary Cancer, Metastatic Gastric Cancer, Metastatic Endometrial Carcinoma	128	China	clinicaltrials.gov
July 20, 2026	NCT07714668	A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer	CSPC Megalith Biopharmaceutical Co.,Ltd.	Phase 2	Recruiting	Ovarian Cancer, Recurrent Ovarian Cancer	171	China	clinicaltrials.gov
July 14, 2026	NCT07702721	Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Observational	Not yet recruiting	Gynecologic Cancer, Cervical Cancer, Endometrial Cancer, Ovary Cancer, Vulvar Cancer	160		clinicaltrials.gov
July 10, 2026	NCT07694427	Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]	GlaxoSmithKline	Phase 3	Recruiting	Ovarian Neoplasms	720	Argentina, Australia, Canada, Japan, South Korea	clinicaltrials.gov
July 9, 2026	NCT07693894	Innovative Ovarian Cancer Biomarker Assays	National and Kapodistrian University of Athens	Observational	Recruiting	Ovarian Cancer	2,080	Czechia, Greece, Lithuania, Portugal, United Kingdom	clinicaltrials.gov
July 8, 2026	NCT07690332	A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα）	NING LI-GYN	Observational	Not yet recruiting	Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer	400		clinicaltrials.gov
July 8, 2026	NCT07690189	Study of NTB-928 in R/R OC	TeneoSeven, Inc.	Phase 1	Recruiting	Relapsed/Refractory Ovarian Carcinoma	90	United States	clinicaltrials.gov
July 6, 2026	NCT07684846	Longitudinal Serum Proteomic Remodeling in Ovarian Cancer	University Medical Centre Ljubljana	Observational	Completed	Ovarian Cancer, Ovarian Cancer Recurrent	33	Slovenia	clinicaltrials.gov
July 6, 2026	NCT07684612	A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With...	GlaxoSmithKline	Phase 3	Recruiting	Ovarian Neoplasms	690	Australia, Canada, Japan, South Korea	clinicaltrials.gov
June 30, 2026	NCT07676890	A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With...	West China Hospital	Phase 1	Recruiting	Ovarian Cancer, mRNA Vaccine	9	China	clinicaltrials.gov
June 30, 2026	NCT07676370	PROV-MESH: Prophylactic Ovarian Cancer MESH	Hospital Vall d'Hebron	Not applicable	Recruiting	Ovarian Cancer	152	Spain	clinicaltrials.gov
June 29, 2026	NCT07674615	IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer	Shanghai Gynecologic Oncology Group	Phase 1	Not yet recruiting	Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary, Primary Peritoneal Carcinoma	19	China	clinicaltrials.gov
June 29, 2026	NCT07673861	Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients	Royal Marsden NHS Foundation Trust	Not applicable	Recruiting	Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST), Colorectal Cancer, Biliary Tract Cancer, Ovarian...	100	United Kingdom	clinicaltrials.gov
June 29, 2026	NCT07673835	Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer（Phase II）	Obstetrics & Gynecology Hospital of Fudan University	Phase 2	Not yet recruiting	Ovarian Cancer	49	China	clinicaltrials.gov
June 26, 2026	NCT07671937	INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study	University of Alabama at Birmingham	Not applicable	Recruiting	Breast Cancer, Corpus Uteri Cancer, Ovary Cancer, Pancreas Cancer, Other Female Genital Malignant Neoplasms	2,748	United States	clinicaltrials.gov
June 26, 2026	NCT07670962	Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy	Asan Medical Center	Observational	Not yet recruiting	Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Ovarian Cancer	300		clinicaltrials.gov
June 26, 2026	NCT07670312	Evaluation of XYA02 in Patients With Advanced Solid Tumors	XYone Therapeutics, Inc	Phase 1/2	Recruiting	MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, GEJ...	190	Australia	clinicaltrials.gov
June 25, 2026	NCT07667751	An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive...	Bai-Rong Xia	Phase 2	Recruiting	Ovary Cancer	35	China	clinicaltrials.gov
June 24, 2026	NCT07667192	Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer	Affidea Nu-med Center of Oncological DIagnostics and Therapy	Observational	Recruiting	Recurrent Gynecologic Cancer, Recurrent Uterine Cancer, Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Recurrent...	500	Poland	clinicaltrials.gov
June 24, 2026	NCT07665515	Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Epitopea Ltd	Phase 1	Recruiting	Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer	50	United Kingdom	clinicaltrials.gov
June 24, 2026	NCT07664735	A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.	Outpace Bio, Inc.	Phase 1	Recruiting	Endometrial Cancer Recurrent, Endometrial Cancer, Advanced Endometrial Cancer, Ovarian Cancer, Ovarian Cancer...	30	United States	clinicaltrials.gov
June 23, 2026	NCT07663513	Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer	Fudan University	Phase 2	Not yet recruiting	Ovarian Cancers	36	China	clinicaltrials.gov
June 22, 2026	NCT07660718	The Use of Artificial Intelligence for Ultrasound Screening of Ovarian Cancer in Postmenopausal Women	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Observational	Active not recruiting	Ovarian Cancer	100	Italy	clinicaltrials.gov
June 18, 2026	NCT07657416	NK521 in the Treatment of Advanced Solid Tumors	Base Therapeutics (Shanghai) Co., Ltd.	Early phase 1	Not yet recruiting	Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites	18	China	clinicaltrials.gov
June 16, 2026	NCT07652073	A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer	Danatlas Pharmaceuticals Co., Ltd	Phase 2	Not yet recruiting	Advanced or Metastatic Ovarian Cancer	30	China	clinicaltrials.gov
June 16, 2026	NCT07651124	To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer	Yong Wha Moon	Not applicable	Recruiting	Recurrent Ovarian Cancer	6	South Korea	clinicaltrials.gov
June 16, 2026	NCT07651020	The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Observational	Completed	Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma, Head and Neck Cancers, Glioblastoma, Colorectal Cancer...	1	China	clinicaltrials.gov
June 15, 2026	NCT07648745	Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer	Prof Gordon Jayson	Phase 2	Completed	Bowel Obstruction, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	30	United Kingdom	clinicaltrials.gov
June 15, 2026	NCT07647653	Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer	Shandong University	Phase 2	Not yet recruiting	Ovarian Cancer	120		clinicaltrials.gov
June 12, 2026	NCT07645716	Evaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards in Gynecologic Oncology	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Observational	Not yet recruiting	Ovarian Neoplasms, Uterine Neoplasms	400	Italy	clinicaltrials.gov
June 11, 2026	NCT07642791	Safety of Opportunistic Salpingectomy During Elective Laparoscopic Cholecystectomy.	University of Zurich	Not applicable	Active not recruiting	Ovarian Cancer, Cholecystolithiasis	300	Switzerland	clinicaltrials.gov
June 10, 2026	NCT07639801	68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors	Peking University Cancer Hospital & Institute	Not applicable	Not yet recruiting	Prostate Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Solid Tumors, Endometrial Cancer, FAPI, PSMA	20		clinicaltrials.gov
June 10, 2026	NCT07638410	Prehabilitation in High-risk Oncologic Surgery	Fox Chase Cancer Center	Not applicable	Recruiting	Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer, Bladder Cancer, Ovarian Cancer, Abdominal...	180	United States	clinicaltrials.gov
June 10, 2026	NCT07637851	Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer	ARCAGY/ GINECO GROUP	Phase 1/2	Not yet recruiting	Ovarian Cancer	43	France	clinicaltrials.gov
June 9, 2026	NCT07636200	The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer	University of Colorado, Boulder	Not applicable	Recruiting	Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only), Glioblastoma, Stage III Ovarian Cancer, Small Cell...	250	United States	clinicaltrials.gov
June 8, 2026	NCT07634094	Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian...	Kalinski, Pawel, MD, PhD	Phase 2	Not yet recruiting	Ovarian Cancer	28	United States	clinicaltrials.gov
June 8, 2026	NCT07631871	An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy	Haihua Yuan	Phase 2	Not yet recruiting	Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm, Urothelial Carcinoma (UC), Pancreatic...	10		clinicaltrials.gov
June 4, 2026	NCT07625137	Preventing Ovarian Cancer Through Opportunistic Salpingectomy at the Time of Laparoscopic Cholecystectomy	University of British Columbia	Not applicable	Not yet recruiting	Salpingectomy, Laparoscopic Cholecystectomy	240	Canada	clinicaltrials.gov

Sponsors posting most

Sponsor	New trials	Latest
Fondazione Policlinico Universitario Agostino Gemelli IRCCS	17	September 8, 2026
AbbVie	6	October 27, 2026
AstraZeneca	6	September 14, 2026
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	5	October 26, 2026
Merck Sharp & Dohme LLC	5	October 13, 2026
Tongji Hospital	5	May 18, 2026
Genmab	4	October 5, 2026
Fudan University	4	August 24, 2026
GlaxoSmithKline	4	July 10, 2026
Beijing Biotech	4	June 1, 2026
Abramson Cancer Center at Penn Medicine	3	November 4, 2026
Peking University Cancer Hospital & Institute	3	September 28, 2026
Incyte Corporation	3	September 1, 2026
Daiichi Sankyo	3	August 28, 2026
Peking University Third Hospital	3	August 12, 2026
Shanghai Gynecologic Oncology Group	3	June 29, 2026
IRCCS Azienda Ospedaliero-Universitaria di Bologna	3	June 22, 2026
Essen Biotech	3	February 13, 2026
Yonsei University	3	January 14, 2026
Mayo Clinic	3	December 16, 2025

By phase

Phase	New trials	Latest
Observational	91	October 27, 2026
Not applicable	78	November 4, 2026
Phase 1	62	November 6, 2026
Phase 2	60	September 28, 2026
Phase 1/2	46	November 2, 2026
Phase 3	32	November 9, 2026
Early phase 1	8	August 27, 2026
Phase 2/3	6	April 24, 2026
Phase 4	4	March 13, 2026

By country

Country	New trials	Latest
United States	128	November 4, 2026
China	92	November 6, 2026
Italy	38	October 9, 2026
Spain	28	September 14, 2026
France	26	August 5, 2026
Australia	25	September 14, 2026
South Korea	24	September 14, 2026
United Kingdom	21	August 20, 2026
Canada	20	September 14, 2026
Japan	19	September 14, 2026
Belgium	18	October 28, 2026
Taiwan	15	September 14, 2026
Germany	13	September 14, 2026
Poland	12	October 20, 2026
Brazil	10	September 14, 2026
Czechia	10	September 9, 2026
Israel	9	August 20, 2026
Denmark	9	July 29, 2026
Portugal	8	September 9, 2026
Greece	7	October 22, 2026
Netherlands	7	October 20, 2026
Argentina	7	August 18, 2026
Ireland	7	April 22, 2026
Austria	6	October 27, 2026
Switzerland	6	June 11, 2026

Where the register publishes

U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.